Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.

Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline

Open access

Published version of a preprint

Abstract

A major unanswered question in the dementia field is whether cognitively unimpaired individuals who harbor both Alzheimer’s disease neuropathological hallmarks (that is, amyloid-β plaques and tau neurofibrillary tangles) can preserve their cognition over time or are destined to decline. In this large multicenter amyloid and tau positron emission tomography (PET) study ( n = 1,325), we examined the risk for future progression to mild cognitive impairment and the rate of cognitive decline over time among cognitively unimpaired individuals who were amyloid PET-positive (A + ) and tau PET-positive (T + ) in the medial temporal lobe (A + T MTL + ) and/or in the temporal neocortex (A + T NEO-T + ) and compared them with A + T − and A − T − groups. Cox proportional-hazards models showed a substantially increased risk for progression to mild cognitive impairment in the A + T NEO-T + (hazard ratio (HR) = 19.2, 95% confidence interval (CI) = 10.9–33.7), A + T MTL + (HR = 14.6, 95% CI = 8.1–26.4) and A + T − (HR = 2.4, 95% CI = 1.4–4.3) groups versus the A − T − (reference) group. Both A + T MTL + (HR = 6.0, 95% CI = 3.4–10.6) and A + T NEO-T + (HR = 7.9, 95% CI = 4.7–13.5) groups also showed faster clinical progression to mild cognitive impairment than the A + T − group. Linear mixed-effect models indicated that the A + T NEO-T + ( β = −0.056 ± 0.005, T = −11.55, P < 0.001), A + T MTL + ( β = −0.024 ± 0.005, T = −4.72, P < 0.001) and A + T − ( β = −0.008 ± 0.002, T = −3.46, P < 0.001) groups showed significantly faster longitudinal global cognitive decline compared to the A − T − (reference) group (all P < 0.001). Both A + T NEO-T + ( P < 0.001) and A + T MTL + ( P = 0.002) groups also progressed faster than the A + T − group. In summary, evidence of advanced Alzheimer’s disease pathological changes provided by a combination of abnormal amyloid and tau PET examinations is strongly associated with short-term (that is, 3–5 years) cognitive decline in cognitively unimpaired individuals and is therefore of high clinical relevance.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41591-022-02049-x

Cites

62 of 62 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 NIA-AA versus IWG criteria. Differences in the nomenclature of cognitively unimpaired individuals with (+) or without (−) in vivo biomarker evidence of Aβ (A) and tau (T) pathology in the NIA-AA versus IWG criteria for AD. Note that for the IWG criteria, the presumed ‘risk for progression’ level rises when both A and T biomarkers are positive.
Fig. 1 NIA-AA versus IWG criteria. Differences in the nomenclature of cognitively unimpaired individuals with (+) or without (−) in vivo biomarker evidence of Aβ (A) and tau (T) pathology in the NIA-AA versus IWG criteria for AD. Note that for the IWG criteria, the presumed ‘risk for progression’ level rises when both A and T biomarkers are positive.CC BY · PubMed Central
Fig. 2 Progression to MCI or all-cause dementia in the different AT biomarker profiles. a,d, Survival curves for progression to MCI (a) or all-cause dementia (d) in the different AT biomarker profiles (A−T+: n = 292; A+TMTL+: n = 51; A+TNEO-T+: n = 60) with the A−T− group (n = 781) as the reference, including a table of total number of participants available at each time point. The dashed line in a indicates the time point at which 50% of a group had progressed to MCI. b,e, Forest plots showing the HRs and 95% CIs derived from the survival analyses shown in a (b) and d(e), from Cox regression models including age, sex, education and cohort as covariates. c,f, Forest plots showing the HRs and 95% CIs derived from Cox regression models including age, sex, education and cohort as covariates but now using the A+T− group as the reference with the outcome being progression to MCI (c) and progression to all-cause dementia (f). Statistics from two-sided tests without adjustment for multiple comparisons are reported. *P < 0.01, **P < 0.001.
Fig. 2 Progression to MCI or all-cause dementia in the different AT biomarker profiles. a,d, Survival curves for progression to MCI (a) or all-cause dementia (d) in the different AT biomarker profiles (A−T+: n = 292; A+TMTL+: n = 51; A+TNEO-T+: n = 60) with the A−T− group (n = 781) as the reference, including a table of total number of participants available at each time point. The dashed line in a indicates the time point at which 50% of a group had progressed to MCI. b,e, Forest plots showing the HRs and 95% CIs derived from the survival analyses shown in a (b) and d(e), from Cox regression models including age, sex, education and cohort as covariates. c,f, Forest plots showing the HRs and 95% CIs derived from Cox regression models including age, sex, education and cohort as covariates but now using the A+T− group as the reference with the outcome being progression to MCI (c) and progression to all-cause dementia (f). Statistics from two-sided tests without adjustment for multiple comparisons are reported. *P < 0.01, **P < 0.001.CC BY · PubMed Central
Fig. 3 Longitudinal cognitive decline in the different AT biomarker profiles. a–e, Cognitive trajectories of mPACC5 (a), MMSE (b) and subcomponents of the mPACC5 including delayed episodic memory (c), timed executive function (d) and semantic memory (e) over time in the different AT biomarker profiles. The average regression line for each group was plotted from linear mixed-effect models including age, sex, education and cohort as covariates. Data are anchored to the tau PET visit (time 0); cognitive data up to 1 year before PET was included. The error bands correspond to the 95% CI.
Fig. 3 Longitudinal cognitive decline in the different AT biomarker profiles. a–e, Cognitive trajectories of mPACC5 (a), MMSE (b) and subcomponents of the mPACC5 including delayed episodic memory (c), timed executive function (d) and semantic memory (e) over time in the different AT biomarker profiles. The average regression line for each group was plotted from linear mixed-effect models including age, sex, education and cohort as covariates. Data are anchored to the tau PET visit (time 0); cognitive data up to 1 year before PET was included. The error bands correspond to the 95% CI.CC BY · PubMed Central
Extended Data Fig. 1 Main analyses from Figs. 2 and 3, but now also including the A-T + group. This figure resembles parts of Figs. 2 and 3 of the main manuscript but now also includes the A-T + group. a, Survival curves in relation to progression to MCI in the different AT categories, with the table of total number of participants available at each time point. b, Survival curves in relation to progression to all-cause dementia in the different AT categories, with the table of total number of participants available at each time point. c, d Forest plots showing the hazard ratios and 95% confidence intervals from the survival analyses shown in a and b, from Cox regression models including age, sex, education, and cohort as covariates. Statistical tests were two-sided without adjustment for multiple comparisons. e, Cognitive trajectories of mPACC5 scores over time in the different AT categories f, Cognitive trajectories of MMSE scores over time in the different AT categories. The average regression line for each group was plotted from linear mixed effect models including age, sex, education, and cohort as covariates. The error bands correspond to the 95% confidence interval. Data are anchored to the tau-PET visit (Time 0), and cognitive data up to 1 year prior to PET was included. *p = 0.01, **p < 0.001.
Extended Data Fig. 1 Main analyses from Figs. 2 and 3, but now also including the A-T + group. This figure resembles parts of Figs. 2 and 3 of the main manuscript but now also includes the A-T + group. a, Survival curves in relation to progression to MCI in the different AT categories, with the table of total number of participants available at each time point. b, Survival curves in relation to progression to all-cause dementia in the different AT categories, with the table of total number of participants available at each time point. c, d Forest plots showing the hazard ratios and 95% confidence intervals from the survival analyses shown in a and b, from Cox regression models including age, sex, education, and cohort as covariates. Statistical tests were two-sided without adjustment for multiple comparisons. e, Cognitive trajectories of mPACC5 scores over time in the different AT categories f, Cognitive trajectories of MMSE scores over time in the different AT categories. The average regression line for each group was plotted from linear mixed effect models including age, sex, education, and cohort as covariates. The error bands correspond to the 95% confidence interval. Data are anchored to the tau-PET visit (Time 0), and cognitive data up to 1 year prior to PET was included. *p = 0.01, **p < 0.001.CC BY · PubMed Central
Extended Data Fig. 2 Progression to AD dementia in the different AT categories. a, Survival curves in relation to progression to AD dementia in the main AT categories, with the table of total number of participants available at each time point. b, Survival curves in relation to progression to AD dementia when including the A-T + group, with the table of total number of participants available at each time point. Given the small number of events, the hazard ratios are difficult to interpret, but the A + T-, A + TMTL + and A + TNEO-T + groups had higher HR’s compared to A-T- reference group (all p < 0.001). Pairwise comparisons indicated that both the A + TNEO-T + (p < 0.001) and A + TMTL + (p = 0.008) groups differed from the A + T- group, and the A + TNEO-T + group differed from the A + TMTL + group (p = 0.01).
Extended Data Fig. 2 Progression to AD dementia in the different AT categories. a, Survival curves in relation to progression to AD dementia in the main AT categories, with the table of total number of participants available at each time point. b, Survival curves in relation to progression to AD dementia when including the A-T + group, with the table of total number of participants available at each time point. Given the small number of events, the hazard ratios are difficult to interpret, but the A + T-, A + TMTL + and A + TNEO-T + groups had higher HR’s compared to A-T- reference group (all p < 0.001). Pairwise comparisons indicated that both the A + TNEO-T + (p < 0.001) and A + TMTL + (p = 0.008) groups differed from the A + T- group, and the A + TNEO-T + group differed from the A + TMTL + group (p = 0.01).CC BY · PubMed Central
Extended Data Fig. 3 Cognitive decline on mPACC5 and MMSE in the individual cohorts. a, Cognitive trajectories of mPACC5 scores over time in the different AT categories in each individual cohort. b, Cognitive trajectories of MMSE scores over time in the different AT categories in each individual cohort. The average regression line for each group was plotted from linear mixed effect models including age, sex, and education as covariates. The error bands correspond to the 95% confidence interval. Data are anchored to the tau-PET visit (Time 0), and cognitive data up to 1 year prior to PET was included.
Extended Data Fig. 3 Cognitive decline on mPACC5 and MMSE in the individual cohorts. a, Cognitive trajectories of mPACC5 scores over time in the different AT categories in each individual cohort. b, Cognitive trajectories of MMSE scores over time in the different AT categories in each individual cohort. The average regression line for each group was plotted from linear mixed effect models including age, sex, and education as covariates. The error bands correspond to the 95% confidence interval. Data are anchored to the tau-PET visit (Time 0), and cognitive data up to 1 year prior to PET was included.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 62 references

Cited by

See all 496

Metadata

Authors
Ossenkoppele, R., Pichet Binette, A., Groot, C., Smith, R., Strandberg, O., Palmqvist, S., Stomrud, E., Tideman, P., Ohlsson, T., Jögi, J., Johnson, K., Sperling, R., Dore, V., Masters, C. L., Rowe, C., Visser, D., van Berckel, B. N. M., van der Flier, W. M., Baker, S., Jagust, W. J., Wiste, H. J., Petersen, R. C., Jack, C. R., & Hansson, O.
Affiliations
  • Lund University (SE)
  • Skåne University Hospital (SE)
  • Brigham and Women's Hospital (US)
  • Florey Institute of Neuroscience and Mental Health (AU)
  • Amsterdam Neuroscience (NL)
  • Lawrence Berkeley National Laboratory (US)
  • Mayo Clinic (US)
Corresponding author
  • Ossenkoppele, Rik
  • Hansson, Oskar
Venue
Nature Medicine
Published
2022-11
Volume
28
Issue
11
Pages
2381-2387
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W4308773890
Cited by
496
References
62
Citations by year
2026: 110 · 2025: 171 · 2024: 130 · 2023: 79 · 2022: 5
FWCI
62.45
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Medicine (publishedVersion, cc-by)
  • medRxiv (acceptedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Pure Amsterdam UMC (publishedVersion, cc-by)
  • Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion, cc-by)
  • Minerva Access (University of Melbourne) (submittedVersion, cc-by)
  • Lund University Publications (Lund University) (submittedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
Funders
  • Mayo Clinic (U01 AG006786)
  • Alzheimer's Association (P01AG036694)
  • Massachusetts General Hospital
  • Biogen
  • BrightFocus Foundation (U01 AG006786, A2021013F)
  • EU Joint Programme – Neurodegenerative Disease Research
  • Australian Government
  • GHR Foundation
  • Health~Holland (#LSHM20106)
  • European Commission (EU-FP7, 298314, HORIZON2020)
  • ZonMw (LSHM20106, #73305095007, 10510022110010)
  • Nederlandse Organisatie voor Wetenschappelijk Onderzoek (#73305095007, EU-FP7)
  • Lunds Universitet
  • Knut och Alice Wallenbergs Stiftelse (2017‐0383, 2015.0125, FO2021-0293, 2020-O000028)
  • Vetenskapsrådet (2016-00906, FO2021-0293, 2018-, 2020-O000028, 2017-00383)
  • Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse (2020-O000028, 2020-0314)
  • Hersenstichting
  • Stichting Dioraphte
  • Alzheimer Nederland (LSHM20106)
  • Skånes universitetssjukhus (2020-O000028)
  • Marcus och Amalia Wallenbergs minnesfond (2015.0125)
  • Amsterdam Neuroscience
  • GIESKES-STRIJBIS FONDS
  • Parkinsonfonden (1280/20)
  • Avid Radiopharmaceuticals
  • National Institute on Aging (U01AG006786, AG-006786, F31AG067677, P01AG036694)
  • H2020 European Research Council (949570)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Oncology › Cancer-related cognitive impairment studies
Keywords
amyloid PET, tau PET, cognitively unimpaired individuals, Alzheimer's disease, amyloid plaques, neurofibrillary tangles, mild cognitive impairment, cognitive decline, medial temporal lobe, temporal neocortex, dementia risk, longitudinal cognitive trajectories, neurodegeneration biomarkers
MeSH terms
Alzheimer Disease, Amyloid, Amyloidosis, Brain, Humans, Biomarkers, Amyloid beta-Peptides, tau Proteins, Positron-Emission Tomography, Plaque, Amyloid, Cognitive Dysfunction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline. https://app.cochat.ai/papers/10.1038/s41591-022-02049-x
The paper
Ossenkoppele, R., Pichet Binette, A., Groot, C., Smith, R., Strandberg, O., Palmqvist, S., Stomrud, E., Tideman, P., Ohlsson, T., Jögi, J., Johnson, K., Sperling, R., Dore, V., Masters, C. L., Rowe, C., Visser, D., van Berckel, B. N. M., van der Flier, W. M., Baker, S., . . . Hansson, O. (2022). Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline. Nature Medicine. https://doi.org/10.1038/s41591-022-02049-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.